Articles producció científica> Medicina i Cirurgia

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

  • Identification data

    Identifier: imarina:9296672
    Authors:
    Cuchel, MRaal, FJHegele, RAAl-Rasadi, KArca, MAverna, MBruckert, EFreiberger, TGaudet, DHarada-Shiba, MHudgins, LCKayikcioglu, MMasana, LParhofer, KGvan Lennep, JERSantos, RDStroes, ESGWatts, GFWiegman, AStock, JKTokgözoglu, LSCatapano, ALRay, KK
    Abstract:
    This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy-both pharmacologic intervention and lipoprotein apheresis (LA)-is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
  • Others:

    Author, as appears in the article.: Cuchel, M; Raal, FJ; Hegele, RA; Al-Rasadi, K; Arca, M; Averna, M; Bruckert, E; Freiberger, T; Gaudet, D; Harada-Shiba, M; Hudgins, LC; Kayikcioglu, M; Masana, L; Parhofer, KG; van Lennep, JER; Santos, RD; Stroes, ESG; Watts, GF; Wiegman, A; Stock, JK; Tokgözoglu, LS; Catapano, AL; Ray, KK
    Department: Medicina i Cirurgia
    URV's Author/s: Masana Marín, Luis
    Keywords: Women Treatment Transfer protein inhibitor Homozygous familial hypercholesterolaemia Genetics Diagnosis Clinical guidance women treatment open-label liver-transplantation lipoprotein apheresis life ldl-apheresis integrated guidance genetics experience evolocumab efficacy diagnosis clinical guidance
    Abstract: This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy-both pharmacologic intervention and lipoprotein apheresis (LA)-is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
    Thematic Areas: Saúde coletiva Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Educação física Direito Ciências biológicas ii Ciências biológicas i Cardiology and cardiovascular medicine Cardiac & cardiovascular systems
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: luis.masana@urv.cat
    Author identifier: 0000-0002-0789-4954
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad197/7148157
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: European Heart Journal. 44 (25): 2277-2291
    APA: Cuchel, M; Raal, FJ; Hegele, RA; Al-Rasadi, K; Arca, M; Averna, M; Bruckert, E; Freiberger, T; Gaudet, D; Harada-Shiba, M; Hudgins, LC; Kayikcioglu, M (2023). 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. European Heart Journal, 44(25), 2277-2291. DOI: 10.1093/eurheartj/ehad197
    Article's DOI: 10.1093/eurheartj/ehad197
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine
    Women
    Treatment
    Transfer protein inhibitor
    Homozygous familial hypercholesterolaemia
    Genetics
    Diagnosis
    Clinical guidance
    women
    treatment
    open-label
    liver-transplantation
    lipoprotein apheresis
    life
    ldl-apheresis
    integrated guidance
    genetics
    experience
    evolocumab
    efficacy
    diagnosis
    clinical guidance
    Saúde coletiva
    Nutrição
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Farmacia
    Educação física
    Direito
    Ciências biológicas ii
    Ciências biológicas i
    Cardiology and cardiovascular medicine
    Cardiac & cardiovascular systems
  • Documents:

  • Cerca a google

    Search to google scholar